APA (7th ed.) Citation

Hollestelle, A., Arndt, V., Brenner, H., Burwinkel, B., Marmé, F., & Schneeweiss, A. (2015). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic oncology, 141(2), . https://doi.org/10.1016/j.ygyno.2015.04.034

Chicago Style (17th ed.) Citation

Hollestelle, Antoinette, Volker Arndt, Hermann Brenner, Barbara Burwinkel, Frederik Marmé, and Andreas Schneeweiss. "No Clinical Utility of KRAS Variant Rs61764370 for Ovarian or Breast Cancer." Gynecologic Oncology 141, no. 2 (2015). https://doi.org/10.1016/j.ygyno.2015.04.034.

MLA (9th ed.) Citation

Hollestelle, Antoinette, et al. "No Clinical Utility of KRAS Variant Rs61764370 for Ovarian or Breast Cancer." Gynecologic Oncology, vol. 141, no. 2, 2015, https://doi.org/10.1016/j.ygyno.2015.04.034.